Predictors for drug selection and minimization in pediatric liver transplantation

小儿肝移植药物选择和最小化的预测因子

基本信息

项目摘要

The long term goal of this project is to minimize organ rejection and immunosuppressant toxicity, in each child with liver transplantation (LTx). Pre-LTx lymphocyte depletion permits steroid avoidance and lowers need for Tacrolimus immunosuppression. If underlying mechanisms were better understood, they could be used to reduce further, primary rejection (50%) and recurrent rejection during drug minimization (30%) on this protocol. Preliminary work leads us to hypothesize that donor-specific hyporeactivity and regulatory- suppressive effect are achieved at highly variable intervals among pediatric LTx with early rejection after steroid-free lymphocyte-depleting immunosuppression. We further hypothesize that this variability in immune-modulation is associated with patterns of single nucleotide polymorphisms (SNP) in extended MHC- region genes subserving proliferation, apoptosis, memory and B-cell-dependent functions. A clinical trial at our center will administer steroid-free Tacrolimus after depletion with 5 mg/kg rabbit anti-human-thymocyte globulin (rATG) to 80 children with LTx. The proposed mechanistic addendum study will entail serial peripheral blood samples from all children before and at 1, 3, and 12 months post-LTx. Specific aims are 1. Longitudinal characterization of donor-specific alloreactivity, T-reg/suppressor cells (CD4+CD25+, CD8+28-), and anti-HLA alto-antibodies in each child, 2. Pre-LTx characterization of 29 SNPs distributed among 14 MHC genes, whose preliminary distribution patterns differ significantly between rejectors (biopsy-proven rejection at 60 days post-LTx), and non-rejectors. This will be done in 80 children and their biologic parents. SNPs showing > or < 50% expected transmission from parents to rejectors and whose transmission differs significantly between rejectors and non-rejectors, will be used to identify candidate loci with the transmission disequilibrium test, and 3. Validate potential candidate genes/loci within outcome groups, by a) measuring donor-specific proliferative/apoptotic/memory responses in T- and B-cell subsets by CFSE-MLR, b) whole genome mRNA expression to complement SNP associations, and minimize false-positives, and c) locus- specific gene expression (mRNA) for candidate loci c). If successful, future application of study results could improve pre-LTx drug selection, e.g.,allocating steroids if SNP patterns predict rejection. Also, post-LTx drug minimization could be made safer, e.g., when T-reg/T-sup appear.
该项目的长期目标是尽量减少器官排斥反应和免疫抑制剂毒性, 儿童肝移植(LTx)前LTx淋巴细胞耗竭允许类固醇避免和降低 需要他克莫司免疫抑制剂。如果能更好地理解潜在的机制, 用于进一步减少药物最小化期间的原发性排斥反应(50%)和复发性排斥反应(30%), 这个协议。初步工作使我们假设供体特异性低反应性和调节性- 在儿童LTx早期排斥反应中, 无类固醇淋巴细胞耗竭免疫抑制。我们进一步假设, 免疫调节与延伸的MHC中的单核苷酸多态性(SNP)模式相关, 促进增殖、凋亡、记忆和B细胞依赖功能的区域基因。的临床试验 我中心将在用5 mg/kg兔抗人胸腺细胞耗尽后给予无类固醇的他克莫司 对80例LTx患儿进行rATG检测。拟议的机械增编研究将需要一系列 LTx前和LTx后1个月、3个月和12个月所有儿童的外周血样本。具体目标是1。 供体特异性同种异体反应性、T-reg/抑制细胞(CD 4 + CD 25+、CD 8 +28-)的纵向表征, 和抗HLA alto抗体,2.分布在14个SNP中的29个SNP的Pre-LTx表征 MHC基因,其初步分布模式在排斥者之间显著不同(活检证实 LTx后60天的排斥)和非排斥者。这将在80名儿童及其亲生父母中进行。 SNP显示>或< 50%的预期从父母到拒绝者的传播,并且其传播不同 显着之间的排斥和非排斥,将用于确定候选基因座的传输 不平衡检验; 3.通过a)测量结果组内的潜在候选基因/基因座, 通过CFSE-MLR在T和B细胞亚群中的供体特异性增殖/凋亡/记忆应答,B)整体 基因组mRNA表达以补充SNP关联,并使假阳性最小化,以及c)基因座- 候选基因座的特异性基因表达(mRNA)c)。如果成功,研究结果的未来应用可以 改进的LTx前药物选择,例如,如果SNP模式预测排斥,则分配类固醇。此外,LTx后药物 可以使最小化更安全,例如,当T-reg/T-sup出现时。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Predicting Cellular Rejection With a Cell-Based Assay: Preclinical Evaluation in Children.
  • DOI:
    10.1097/tp.0000000000001076
  • 发表时间:
    2017-01
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Ashokkumar C;Soltys K;Mazariegos G;Bond G;Higgs BW;Ningappa M;Sun Q;Brown A;White J;Levy S;Fazzolare T;Remaley L;Dirling K;Harris P;Hartle T;Kachmar P;Nicely M;OʼToole L;Boehm B;Jativa N;Stanley P;Jaffe R;Ranganathan S;Zeevi A;Sindhi R
  • 通讯作者:
    Sindhi R
Antithymocyte globulin facilitates alloreactive T-cell apoptosis by means of caspase-3: potential implications for monitoring rejection-free outcomes.
  • DOI:
    10.1097/tp.0000000000000289
  • 发表时间:
    2015-01
  • 期刊:
  • 影响因子:
    6.2
  • 作者:
    Ashokkumar C;Sun Q;Ningappa M;Higgs BW;Mazariegos G;Zeevi A;Sindhi R
  • 通讯作者:
    Sindhi R
Profile of the Pleximmune blood test for transplant rejection risk prediction.
用于预测移植排斥风险的 Pleximune 血液测试概况。
  • DOI:
    10.1586/14737159.2016.1139455
  • 发表时间:
    2016
  • 期刊:
  • 影响因子:
    5.1
  • 作者:
    Sindhi,Rakesh;Ashokkumar,Chethan;Higgs,BrandonW;Levy,Samantha;Soltys,Kyle;Bond,Geoffrey;Mazariegos,George;Ranganathan,Sarangarajan;Zeevi,Adriana
  • 通讯作者:
    Zeevi,Adriana
A network-based approach to identify expression modules underlying rejection in pediatric liver transplantation.
  • DOI:
    10.1016/j.xcrm.2022.100605
  • 发表时间:
    2022-04-19
  • 期刊:
  • 影响因子:
    14.3
  • 作者:
    Ningappa, Mylarappa;Rahman, Syed A.;Higgs, Brandon W.;Ashokkumar, Chethan S.;Sahni, Nidhi;Sindhi, Rakesh;Das, Jishnu
  • 通讯作者:
    Das, Jishnu
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAKESH K. SINDHI其他文献

RAKESH K. SINDHI的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAKESH K. SINDHI', 18)}}的其他基金

Mapping Disease Pathways for Biliary Atresia
绘制胆道闭锁的疾病途径
  • 批准号:
    9904315
  • 财政年份:
    2017
  • 资助金额:
    $ 39.36万
  • 项目类别:
Predictors for drug selection and minimization in pediatric liver transplantation
小儿肝移植药物选择和最小化的预测因素
  • 批准号:
    7289728
  • 财政年份:
    2006
  • 资助金额:
    $ 39.36万
  • 项目类别:
Predictors for drug selection and minimization in pediatric liver transplantation
小儿肝移植药物选择和最小化的预测因子
  • 批准号:
    7251717
  • 财政年份:
    2006
  • 资助金额:
    $ 39.36万
  • 项目类别:
Predictors for drug selection and minimization in pediatric liver transplantation
小儿肝移植药物选择和最小化的预测因子
  • 批准号:
    7489428
  • 财政年份:
    2006
  • 资助金额:
    $ 39.36万
  • 项目类别:
PHARMACOKINETICS OF SIROLIMUS CONVERSION IN PEDIATRIC LIVER TRANSPLANT
小儿肝移植中西罗莫司转化的药代动力学
  • 批准号:
    7203140
  • 财政年份:
    2005
  • 资助金额:
    $ 39.36万
  • 项目类别:
PHARMACODYNAMIC THRESHOLDS OF IMMUNOSUPPRESSION
免疫抑制的药效阈值
  • 批准号:
    7203103
  • 财政年份:
    2005
  • 资助金额:
    $ 39.36万
  • 项目类别:
STEROID-FREE IMMUNOSUPRESSION WITH SIROLIUMS & TACROLIMUS IN PRIMARY PEDIATRIC
使用西罗林进行无类固醇免疫抑制
  • 批准号:
    7203102
  • 财政年份:
    2005
  • 资助金额:
    $ 39.36万
  • 项目类别:
Pharmacodynamic Thresholds of Immunosuppression in Transplant Recipients
移植受者免疫抑制的药效阈值
  • 批准号:
    7041319
  • 财政年份:
    2003
  • 资助金额:
    $ 39.36万
  • 项目类别:
Pharmacodynamic Thresholds of Immunosuppression
免疫抑制的药效阈值
  • 批准号:
    7041293
  • 财政年份:
    2003
  • 资助金额:
    $ 39.36万
  • 项目类别:
Steroid-Free Immunosupression with Sirolimus & Tacrolimu
使用西罗莫司进行无类固醇免疫抑制
  • 批准号:
    7041292
  • 财政年份:
    2003
  • 资助金额:
    $ 39.36万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 39.36万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 39.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 39.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 39.36万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 39.36万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 39.36万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 39.36万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 39.36万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 39.36万
  • 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
  • 批准号:
    RGPIN-2018-04753
  • 财政年份:
    2022
  • 资助金额:
    $ 39.36万
  • 项目类别:
    Discovery Grants Program - Individual
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了